While Sarepta Therapeutics Inc has underperformed by -0.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT rose by 25.05%, with highs and lows ranging from $173.25 to $89.92, whereas the simple moving average fell by -7.87% in the last 200 days.
On November 27, 2024, Needham Reiterated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Buy. A report published by H.C. Wainwright on November 25, 2024, Initiated its previous ‘Sell’ rating for SRPT. Cantor Fitzgerald also Upgraded SRPT shares as ‘Overweight’, setting a target price of $167 on the company’s shares in a report dated November 07, 2024. Jefferies Initiated an Buy rating on October 21, 2024, and assigned a price target of $165. Raymond James initiated its ‘Outperform’ rating for SRPT, as published in its report on October 10, 2024. RBC Capital Mkts’s report from July 29, 2024 suggests a price prediction of $182 for SRPT shares, giving the stock a ‘Outperform’ rating. Citigroup also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Sarepta Therapeutics Inc (SRPT)
Further, the quarter-over-quarter increase in sales is 40.79%, showing a positive trend in the upcoming months.
Sarepta Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 12.27% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and SRPT has an average volume of 960.24K. On a monthly basis, the volatility of the stock is set at 3.83%, whereas on a weekly basis, it is put at 3.83%, with a loss of -4.02% over the past seven days. Furthermore, long-term investors anticipate a median target price of $186.95, showing growth from the present price of $119.47, which can serve as yet another indication of whether SRPT is worth investing in or should be passed over.
How Do You Analyze Sarepta Therapeutics Inc Shares?
Biotechnology giant Sarepta Therapeutics Inc (SRPT) is based in the USA and is one of the largest companies in the market. When comparing Sarepta Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 99.24, there is a growth in quarterly earnings of 173.55%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 6.91%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.96% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SRPT shares are owned by institutional investors to the tune of 89.96% at present.
